



## MaaT Pharma: Half-year Report and an Increase of the Resources Allocated to the Liquidity Contract With Kepler Cheuvreux

Lyon, France, July 5<sup>th</sup>, 2024 – 6:00 pm CET – [MaaT Pharma](#) (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer, today announces its half-year report on the liquidity contract with the firm Kepler Cheuvreux and an increase of €50,000 to the resources allocated to the contract, in accordance with the provisions of article 4 of AMF decision no. 2021-01 of June 22, 2021.

Under the liquidity contract entered into between MaaT Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30<sup>th</sup>, 2024:

- 26,929 shares
- € 17,089.40
- Number of executions on buy side on semester: 933
- Number of executions on sell side on semester: 1,014
- Traded volume on buy side on semester: 28,959 shares for € 237,891.32
- Traded volume on sell side on semester: 26,266 shares for € 220,168.07

As a reminder:

- the following resources appeared on the last half year statement on December 31, 2023 on the liquidity account:
  - 24,236 shares
  - € 34,107.60
  - Number of executions on buy side on semester: 627
  - Number of executions on sell side on semester: 368
  - Traded volume on buy side on semester: 18,328 shares for € 122,340.49
  - Traded volume on sell side on semester: 9,576 shares for € 64,693.03
- the following resources appeared on the liquidity account when the activity started:
  - 0 shares
  - € 200,000.00

Following the addition of these resources for the amount of €50,000, the position on July 4<sup>th</sup>, 2024, is:

- 26,006 shares
- € 74,303.08

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22<sup>nd</sup>, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>933</b>	<b>28,959</b>	<b>237,891.32</b>	<b>1,014</b>	<b>26,266</b>	<b>220,168.07</b>
01/02/2024	-	-	-	9	102	719.10
01/03/2024	3	60	448.80	15	435	3,275.55
01/04/2024	9	126	948.78	8	211	1,612.04
01/05/2024	2	45	339.30	3	90	689.40
01/08/2024	18	410	2,886.40	-	-	-
01/09/2024	11	340	2,237.20	15	425	2,843.25
01/10/2024	5	130	877.50	2	72	487.44
01/11/2024	2	2	13.74	10	241	1,679.77
01/12/2024	4	50	351.00	2	70	501.20
01/15/2024	8	203	1,408.82	8	110	779.90
01/16/2024	3	36	252.00	3	35	246.40
01/17/2024	5	70	482.30	-	-	-
01/18/2024	5	151	1,026.80	-	-	-
01/19/2024	10	222	1,469.64	1	30	201.00
01/22/2024	3	50	351.00	27	641	4,512.64
01/23/2024	-	-	-	5	93	672.39
01/24/2024	7	175	1,242.50	4	130	928.20
01/25/2024	5	71	506.94	2	36	257.76
01/26/2024	3	10	71.50	4	93	668.67
01/29/2024	7	141	1,022.25	8	155	1,148.55
01/30/2024	2	21	151.20	2	36	260.64
01/31/2024	4	110	784.30	6	148	1,061.16
02/01/2024	3	60	430.80	2	42	304.50
02/02/2024	8	160	1,142.40	8	150	1,087.50
02/05/2024	-	-	-	2	35	250.95
02/06/2024	3	70	497.00	5	105	753.90
02/07/2024	4	85	606.05	-	-	-
02/08/2024	2	21	149.94	5	83	593.45
02/09/2024	10	185	1,311.65	6	118	859.04
02/12/2024	7	127	896.62	1	1	7.22
02/13/2024	1	1	7.02	4	24	169.44
02/14/2024	4	69	481.62	2	32	227.20
02/15/2024	3	26	182.52	10	151	1,069.08
02/16/2024	2	30	213.00	3	41	293.15
02/19/2024	7	130	928.20	17	280	2,027.20
02/20/2024	-	-	-	15	329	2,470.79
02/21/2024	9	130	964.60	-	-	-
02/22/2024	-	-	-	9	115	865.95
02/23/2024	1	1	7.62	53	1,131	9,398.61
02/26/2024	26	550	4,526.50	9	103	850.78
02/27/2024	6	75	612.00	13	277	2,310.18
02/28/2024	45	880	6,758.40	23	706	5,655.06
02/29/2024	15	211	1,673.23	3	34	270.30
03/01/2024	4	90	711.00	10	200	1,606.00
03/04/2024	14	260	2,048.80	7	130	1,036.10
03/05/2024	9	162	1,263.60	10	133	1,046.71
03/06/2024	11	245	2,035.95	53	1,009	8,465.51
03/07/2024	2	20	170.40	21	260	2,236.00
03/08/2024	17	335	2,814.00	6	94	797.12
03/11/2024	7	114	992.94	22	381	3,341.37

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>933</b>	<b>28,959</b>	<b>237,891.32</b>	<b>1,014</b>	<b>26,266</b>	<b>220,168.07</b>
03/12/2024	7	139	1,234.32	10	316	2,837.68
03/13/2024	1	35	315.00	25	1,039	9,735.43
03/14/2024	30	921	8,427.15	13	319	2,992.22
03/15/2024	11	291	2,697.57	28	632	5,890.24
03/18/2024	5	99	903.87	3	45	413.55
03/19/2024	-	-	-	6	74	682.28
03/20/2024	20	553	4,943.82	13	328	2,971.68
03/21/2024	8	370	3,204.20	3	55	480.70
03/22/2024	6	125	1,113.75	19	422	3,798.00
03/25/2024	12	193	1,796.83	16	481	4,540.64
03/26/2024	6	158	1,448.86	8	173	1,600.25
03/27/2024	1	50	465.00	6	258	2,414.88
03/28/2024	22	692	6,304.12	8	343	3,217.34
04/02/2024	5	185	1,626.15	6	185	1,635.40
04/03/2024	4	56	495.60	1	1	8.86
04/04/2024	-	-	-	4	90	808.20
04/05/2024	-	-	-	17	435	4,023.75
04/08/2024	9	256	2,403.84	26	626	5,959.52
04/09/2024	8	133	1,263.50	10	444	4,253.52
04/10/2024	-	-	-	7	226	2,171.86
04/11/2024	2	36	342.00	5	33	316.47
04/12/2024	2	20	189.60	1	1	9.56
04/15/2024	41	1,314	12,246.48	25	785	7,622.35
04/16/2024	4	125	1,140.00	14	325	2,996.50
04/17/2024	13	578	5,138.42	-	-	-
04/18/2024	3	101	906.98	5	266	2,420.60
04/19/2024	21	1,779	15,726.36	7	304	2,723.84
04/22/2024	4	330	2,864.40	11	593	5,200.61
04/23/2024	3	124	1,088.72	6	157	1,389.45
04/24/2024	6	217	1,907.43	2	2	17.62
04/25/2024	1	1	8.80	12	468	4,165.20
04/26/2024	2	130	1,170.00	3	29	262.74
04/29/2024	6	285	2,676.15	20	652	6,109.24
04/30/2024	6	354	3,313.44	3	105	996.45
05/02/2024	5	221	2,048.67	2	80	747.20
05/03/2024	1	1	9.24	7	264	2,460.48
05/06/2024	10	323	3,007.13	4	91	849.94
05/07/2024	4	244	2,286.28	12	466	4,385.06
05/08/2024	1	20	188.00	1	5	47.30
05/09/2024	-	-	-	1	95	898.70
05/10/2024	6	161	1,513.40	2	39	368.94
05/13/2024	2	103	968.20	2	101	952.43
05/14/2024	2	77	719.18	2	84	788.76
05/15/2024	55	3,305	27,695.90	5	150	1,281.00
05/16/2024	7	340	2,692.80	9	260	2,072.20
05/17/2024	12	387	3,154.05	15	325	2,668.25
05/20/2024	8	325	2,665.00	7	205	1,693.30
05/21/2024	7	265	2,130.60	4	200	1,624.00
05/22/2024	11	344	2,752.00	3	88	719.84
05/23/2024	3	62	494.76	6	130	1,040.00

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>933</b>	<b>28,959</b>	<b>237,891.32</b>	<b>1,014</b>	<b>26,266</b>	<b>220,168.07</b>
05/24/2024	6	308	2,439.36	8	230	1,826.20
05/27/2024	1	15	119.10	2	80	640.80
05/28/2024	2	70	558.60	3	55	443.30
05/29/2024	8	212	1,704.48	5	129	1,046.19
05/30/2024	8	313	2,500.87	4	88	709.28
05/31/2024	8	451	3,598.98	1	1	8.04
06/03/2024	3	150	1,194.00	3	50	400.00
06/04/2024	6	200	1,586.00	4	110	875.60
06/05/2024	5	119	940.10	5	100	794.00
06/06/2024	7	250	1,970.00	1	1	7.94
06/07/2024	6	214	1,697.02	8	140	1,113.00
06/10/2024	9	305	2,400.35	1	40	316.80
06/11/2024	5	200	1,560.00	5	212	1,670.56
06/12/2024	3	105	807.45	1	50	385.00
06/13/2024	5	163	1,253.47	4	125	965.00
06/14/2024	17	440	3,291.20	2	57	434.91
06/17/2024	26	700	4,704.00	6	285	1,915.20
06/18/2024	3	60	403.80	7	355	2,410.45
06/19/2024	10	591	3,953.79	3	39	267.54
06/20/2024	4	68	450.84	7	150	1,009.50
06/21/2024	2	51	346.80	5	303	2,084.64
06/24/2024	1	19	131.10	7	174	1,211.04
06/25/2024	7	150	1,081.50	10	360	2,610.00
06/26/2024	-	-	-	26	944	7,174.40
06/27/2024	19	613	4,677.19	4	89	688.86
06/28/2024	23	904	6,535.92	4	187	1,357.62

## About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).



## Contacts

### MaaT Pharma – Investor Relations

Guillaume DEBROAS, Ph.D.  
Head of Investor Relations  
+33 6 16 48 92 50  
[invest@maat-pharma.com](mailto:invest@maat-pharma.com)

### MaaT Pharma – Media Relations

Pauline RICHAUD  
Senior PR & Corporate Communications Manager  
+33 6 14 06 45 92  
[media@maat-pharma.com](mailto:media@maat-pharma.com)

### Trophic Communications

Jacob VERGHESE or  
Desmond JAMES  
+49 151 7441 6179  
[maat@trophic.eu](mailto:maat@trophic.eu)